Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Categories
  3. Pharmacology

Pharmacology Research

Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.

Showing 111-120 of 639 results

PharmacologyNeurologyPain Management

Pharmacological Evidence of the Important Roles of CCR1 and CCR3 and Their Endogenous Ligands CCL2/7/8 in Hypersensitivity Based on a Murine Model of Neuropathic Pain

Cells, 2023 • December 26, 2022

This study comprehensively investigates the roles of CCR1, CCR3, and their endogenous ligands in neuropathic pain using a murine model of chronic constriction injury (CCI). The research identifies tim...

KEY FINDING: CCL2/7/8 protein levels were significantly increased in the spinal cord following chronic constriction injury (CCI) of the sciatic nerve, suggesting their involvement in both the development and maintenance of neuropathic pain.

Read Summary
PharmacologyNeurologyGenetics

Nrf2 Activation: Involvement in Central Nervous System Traumatic Injuries. A Promising Therapeutic Target of Natural Compounds

Int. J. Mol. Sci., 2023 • December 22, 2022

This review provides an overview of preclinical studies that highlight the positive effects of natural bioactive compounds in SCI and TBI experimental models through the activation of the Nrf2 pathway...

KEY FINDING: Several natural compounds can activate Nrf2 through multiple pathways, inducing a strong antioxidant response against CNS trauma.

Read Summary
PharmacologyImmunologyPain Management

New insights into the analgesic properties of the XCL1/XCR1 and XCL1/ITGA9 axes modulation under neuropathic pain conditions - evidence from animal studies

Frontiers in Immunology, 2022 • December 22, 2022

The study investigates the role of the XCL1 chemokine and its receptors, XCR1 and ITGA9, in neuropathic pain using a chronic constriction injury (CCI) model in mice. Key findings include the upregulat...

KEY FINDING: XCL1 expression increases in the spinal cord after nerve injury and is mainly produced by astroglial cells.

Read Summary
Spinal Cord InjuryPharmacologyBiomedical

Barrier-penetrating liposome targeted delivery of basic fibroblast growth factor for spinal cord injury repair

Materials Today Bio, 2023 • January 7, 2023

This research focuses on developing a dual-targeting liposome (bFGF@Lip-Cp&Rp) to deliver basic fibroblast growth factor (bFGF) for spinal cord injury (SCI) treatment, addressing the challenges of dru...

KEY FINDING: The dual-targeted liposomes (bFGF@Lip-Cp&Rp) can effectively cross the BSCB and accumulate at the injury site in SCI rats.

Read Summary
PharmacologyNeurologyGenetics

Contribution of Nischarin/IRAS in CNS development, injury and diseases

Journal of Advanced Research, 2023 • January 27, 2023

This review systematically analyzes the role and mechanism of Nischarin/IRAS in the CNS, providing references and possible targets for neurological disease treatment and broadening the direction of Ni...

KEY FINDING: Nischarin/IRAS expression in the CNS is closely associated with the regulation of brain development, especially neuronal migration.

Read Summary
PharmacologyPain Management

Targeting the VEGF-A/Neuropilin 1 axis for relief of neuropathic pain

Pain, 2023 • July 1, 2023

The study identifies the VEGF-A/NRP1 interaction as a potential target for pain relief. Blocking this interaction with the compound NRP1-4 decreases sensory neuron excitability. NRP1-4 reduces pain-re...

KEY FINDING: NRP1–4 blocks the increase in excitability of sensory neurons caused by VEGF-A, suggesting it interferes with VEGF-A's action on these neurons.

Read Summary
PharmacologyMental HealthNeurology

The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling

Journal of Translational Medicine, 2023 • January 23, 2023

Our present study results suggest that elevated levels of sEH play an important role in neuropathic pain with anhedonia(Fig.  6). Moreover, TPPU may alleviate the anhedonia and pain behaviors in two w...

KEY FINDING: In anhedonia-susceptible mice, the tissue levels of sEH were significantly increased in the medial prefrontal cortex (mPFC), hippocampus, spinal cord, liver, kidney, and gut.

Read Summary
Spinal Cord InjuryAlternative MedicinePharmacology

Systematically Investigating the Pharmacological Mechanism of Momordica grosvenori in the Treatment of Spinal Cord Injury by Network Pharmacology and Experimental Verification

Evidence-Based Complementary and Alternative Medicine, 2023 • January 25, 2023

The study aimed to explore the molecular mechanism of Momordica grosvenori (MG) in spinal cord injury (SCI) by network pharmacology analysis. The current work indicated that MG might play an anti-SCI ...

KEY FINDING: The study identified 293 MG-anti-SCI targets by intersecting MG-related targets and SCI-related targets.

Read Summary
Cardiovascular SciencePharmacologyNeurology

Cav1.3-selective inhibitors of voltage-gated L-type Ca2+ channels: Fact or (still) fiction?

British Journal of Pharmacology, 2023 • May 1, 2023

This review assesses the existing evidence for Cav1.3-selective calcium channel blockers, which are of interest for treating various diseases. It finds that currently available compounds lack sufficie...

KEY FINDING: Current Cav1.3-selective blockers lack validation. The review finds no pharmacological tools suitable to confirm or refute a role of Cav1.3 channels in cellular responses due to selectivity issues.

Read Summary
Spinal Cord InjuryPharmacologyNeurology

Network pharmacology integrated with experimental validation to explore the therapeutic role and potential mechanism of Epimedium for spinal cord injury

Frontiers in Molecular Neuroscience, 2023 • January 30, 2023

This study investigated the therapeutic potential of Epimedium (EPI) for spinal cord injury (SCI) using network pharmacology and experimental validation. The research identified active ingredients and...

KEY FINDING: EPI improves behavioral performance in SCI rats, as indicated by improved Basso, Beattie, and Bresnahan scores.

Read Summary
Previous
1...111213...64
Next